Sciderm GmbH   Report issue

For profit Phase 2 Phase 3
Founded: Hamburg Germany (2005)
Status: Acquired by TFS Trial Form Support (2016)

Organization Overview

First Clinical Trial
2011
NCT01360944
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2017

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Active Ingredients

Drugs in Phase 3 Trials (1)

naltrexone (revia) (1 trial)

Drugs in Phase 2 Trials (3)

estradiol (progynon depot) (1 trial)

jnj-61178104 (1 trial)

las41004 (1 trial)

Drugs in Other Trials (2)

apremilast (otezla) (1 trial)

fumaric acid esters (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Psoriasis (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 4
  • # of Trial APIs: 6